CAMK2A and central nervous system cancer: The higher level of expression of RAB3A, SYP, CAMK2A, and GABRA1 in glioma patients was associated with improved OS and DFS (Figures 6(a), 6(a)-6(d), 6(f)-6(g), 6(i)-6(j), and 6(l)), whereas the higher level of expression of TYROBP and VSIG4 was associated with reduced OS and DFS (Figures 6(b), 6(e), 6(h), and 6(k)).